[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Zhongshan Hospital Xiamen University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":113},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,68,91],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100651042","inflammatory-markers-and-prognosis-after-cerebral-thrombectomy-in-large-vessel-occlusion-100651042",false,"NCT07754942","Inflammatory Markers and Prognosis After Cerebral Thrombectomy in Large Vessel Occlusion","Local-to-Systemic Inflammatory Biomarker Gradients and 90-Day Functional Outcomes in Patients With Acute Ischemic Stroke Due to Anterior Circulation Large Vessel Occlusion Undergoing Mechanical Thrombectomy: A Prospective Observational Cohort Study","IMPACT-LVO","Inclusion Criteria:\n\n* Age 18 years or older.\n* Acute ischemic stroke caused by anterior circulation large vessel occlusion, confirmed by routine vascular imaging or digital subtraction angiography.\n* Undergoing clinically indicated mechanical thrombectomy according to routine clinical practice.\n* Provision of written informed consent by the participant or legally authorized representative, in accordance with local ethics requirements.\n\nExclusion Criteria:\n\n* Posterior circulation large vessel occlusion.\n* Mechanical thrombectomy not performed.\n* Known active systemic infection, active malignancy, or chronic inflammatory\u002Fautoimmune disease requiring systemic immunosuppressive treatment, when these conditions are expected to substantially affect inflammatory biomarker measurements.\n* Pregnancy or breastfeeding, if required by the local ethics committee.\n* Enrollment in another interventional study that could affect inflammatory biomarker measurements or clinical outcome assessment.\n* Inability to obtain informed consent, where consent from a legally authorized representative is not permitted or cannot be obtained.","ALL","18 Years",{"count":20,"type":21},50,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to describe the local change in interleukin-6 (IL-6) across a blood clot in adults with acute ischemic stroke caused by anterior circulation large vessel occlusion who are undergoing mechanical thrombectomy.\n\nThe main questions it aims to answer are:\n\n* Is the level of IL-6 different in arterial blood collected beyond the clot compared with arterial blood collected before the clot during mechanical thrombectomy?\n* Is the trans-thrombus IL-6 difference associated with functional independence 90 days after stroke and with complications related to reperfusion injury? There is no comparison group and no experimental treatment. Researchers will compare paired blood samples collected from opposite sides of the clot in the same participant. Blood collected from a peripheral vein at hospital admission will be used only as a supportive reference for systemic inflammation.\n\nParticipants will:\n\n* Receive standard mechanical thrombectomy and stroke care determined by their treating clinical team.\n* Have small blood samples collected at planned time points, including paired arterial blood samples collected during the thrombectomy procedure.\n* Have clinical and imaging information collected from their medical records and have functional status assessed 90 days after stroke.\n\nThe study will not delay or change standard stroke treatment.",[25,26],"Acute Ischemic Stroke","Large Vessel Occlusion",[28,29,30,31,32,33,34],"Mechanical Thrombectomy","Anterior Circulation Large Vessel Occlusion","Trans-Thrombus Gradient","Inflammatory Biomarkers","Reperfusion Injury","Modified Rankin Scale","Interleukin-6","NOT_YET_RECRUITING","2026-08-04",{"date":38,"type":39},"2026-08-10","ACTUAL",{"date":41,"type":21},"2026-08-01",{"date":43,"type":21},"2029-08-01",{"name":45,"class":46},"Zhongshan Hospital Xiamen University","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100646892","recurrence-mechanisms-of-colorectal-adenoma-after-resection-and-a-multi-omics-research-protocol-100646892","NCT07683312","Recurrence Mechanisms of Colorectal Adenoma After Resection and a Multi-Omics Research Protocol","RM-CAR-MRP","Inclusion Criteria:\n\n* Patients with colorectal adenoma confirmed by initial endoscopic examination and pathological diagnosis.\n\nExclusion Criteria:\n\nUse of antibiotics within the past 2 weeks; Patients without colorectal adenoma; Patients with familial adenomatous polyposis; Patients with special dietary habits, such as vegetarians, alcoholics, binge eaters, or anorexic patients, etc.",{"count":56,"type":21},30,"We aim to establish a single-cell atlas of primary adenomas, recurrent adenomas, and paired normal mucosa, identify recurrence-associated cell subpopulations and transcriptional pathways, and construct a risk prediction model for recurrence (integrating multi-omics features and clinical variables). Ultimately, we propose a panel of biomarkers that can be used to optimize follow-up strategies and guide potential microbiome-based interventions.\n\nUnder the premise of meeting routine clinicopathological requirements, we will collect tissue samples from 30 patients with colorectal adenomas. Each collected adenoma sample will be divided into three equal portions for scRNA-seq, scATAC-seq, and microbiome diversity sequencing, respectively. Two years after sampling, enrolled patients will undergo follow-up colonoscopy. Those in whom adenomas are detected will be classified as the recurrence group, while those without adenomas will be classified as the non-recurrence group. Sequencing data will be jointly analyzed in conjunction with clinical medical records. The tissue specimens obtained will not affect routine diagnosis or treatment outcomes.",[59],"Colorectal Adenoma and Carcinoma","2026-06-28",{"date":62,"type":39},"2026-07-06",{"date":64,"type":21},"2026-06-27",{"date":66,"type":21},"2029-12-30",{"name":45,"class":46},{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":17,"minAge":18,"maxAge":75,"enrollmentInfo":76,"targetDuration":78,"studyType":22,"phases":4,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":88,"leadSponsor":90,"locationsCount":47},"100609283","analysis-of-differences-in-small-intestinal-microbiota-structure-and-metabolites-between-patients-with-irritable-bowel-syndrome-and-healthy-individuals-100609283","NCT07212569","Analysis of Differences in Small Intestinal Microbiota Structure and Metabolites Between Patients With Irritable Bowel Syndrome and Healthy Individuals","Inclusion Criteria:\n\nExperimental Group： Aged 18-65 years, male or female. Meets the Rome IV diagnostic criteria for IBS The absence of organic gastrointestinal disease that could explain the symptoms.\n\nProvides informed consent and voluntarily signs the informed consent form. Control Group： Age and sex-matched to the IBS patient group. No history of chronic digestive diseases or current gastrointestinal symptoms. Has not used antibiotics, proton pump inhibitors, probiotics, or other medications known to affect gut microbiota within the past month.\n\nProvides informed consent and voluntarily signs the informed consent form.\n\nExclusion Criteria:\n\nHistory of gastrointestinal surgery (excluding appendectomy). Presence of concomitant organic gastrointestinal diseases (e.g., inflammatory bowel disease, celiac disease, gastrointestinal tumors).\n\nPresence of severe concomitant cardiac, hepatic, renal, endocrine, hematologic, or neurological diseases.\n\nLong-term use of medications known to affect gastrointestinal motility (e.g., opioids).\n\nPregnancy, lactation, or women planning a pregnancy. Conditions contraindicating the use of capsule endoscopy, such as dysphagia, or known gastrointestinal strictures, diverticula, or obstruction.\n\nAny other condition deemed by the investigator as unsuitable for participation in the study.",true,"65 Years",{"count":77,"type":21},90,"6 Months","Irritable Bowel Syndrome (IBS) is a common functional bowel disorder with complex and not yet fully elucidated pathophysiological mechanisms. Recent research suggests that gut microbiota dysbiosis, particularly small intestinal bacterial overgrowth (SIBO), may play a key role in the generation of IBS symptoms. However, the vast majority of current studies have focused on fecal samples, which primarily reflect the colonic microbiota. The small intestinal microbiota, which is directly involved in nutrient digestion and absorption and more prone to dysbiosis, remains understudied due to the challenges in obtaining samples.",[81],"Irritable Bowel Syndrome",[81,83],"small intestinal microbiota","2025-10-01",{"date":86,"type":39},"2025-10-08",{"date":84,"type":21},{"date":89,"type":21},"2028-12-01",{"name":45,"class":46},{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":74,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":47},"100556819","exploring-the-risk-factors-of-otomycosis-a-case-control-study-100556819","NCT06530069","Exploring the Risk Factors of Otomycosis: A Case-Control Study","Inclusion Criteria:\n\n* Symptoms in the case group include tinnitus, ear fullness or blockage, itching, ear pain, discharge, and hearing loss. Physical examination reveals the presence of hyphae, scabs, secretions, masses, pus, red skin, erosion, swelling, or granulation in the ear canal. Laboratory fungal cultures must be positive. The control group does not have the aforementioned ear symptoms and has not sought medical attention for ear-related symptoms.\n\nExclusion Criteria:\n\n* Patients with otitis media, tympanic membrane perforation, or post-radiotherapy.",{"count":98,"type":21},200,"The goal of this observational study is to explore the risk factors of fungal otitis externa in the fungal otitis externa patients The main question it aims to answer is:\n\nWhat behaviors lead to the occurrence of fungal otitis externa? Participants will complete a detailed questionnaire survey. If there is a comparison group: Researchers will compare the healthy group and the disease group to see if there are any differences.",[101],"Otomycosis",[101,103],"predisposing factor","RECRUITING","2024-08-07",{"date":107,"type":39},"2024-08-09",{"date":109,"type":39},"2024-08-01",{"date":111,"type":21},"2024-08-15",{"name":45,"class":46},""]